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Abstract
The aim of this 2-year longitudinal observational study was to
explore hand bone loss as a disease outcome measure in
established rheumatoid arthritis (RA).
A cohort of 215 patients with RA (170 women and 45 men,
aged 20–70 years) were recruited from the Oslo RA registry
and studied for changes in hand bone mass during a 2-year
follow-up. Digital X-ray radiogrammetry (DXR) was used to
measure cortical hand bone mineral density (BMD) and
metacarpal cortical index, whereas dual-energy X-ray
absorptiometry (DXA) was used to assess whole hand BMD,
which measures total cortical and trabecular bone. DXA-BMD
total hip and spine and informative data for disease and therapy
were also collected.
Hand bone loss could be revealed over a 2-year follow-up
measured by DXR-BMD (-0.90%, P < 0.01), but not by DXA-
BMD (0.00%, P = 0.87). DXA-BMD hand bone loss was only
observed in patients with disease duration ≤3 years and not in
patients with longer disease duration (-0.96% versus 0.24%, P
< 0.01), whereas loss of DXR-BMD was independent of disease
duration. Disease activity (measured by the disease activity
score including 28 joints) independently predicted loss of DXR-
BMD but not changes in the DXA-BMD hand in the multivariate
analysis. The change in DXR metacarpal cortical index was
highly correlated to DXR-BMD (r = 0.94, P < 0.001).
These data suggest that DXR-BMD may be a more appropriate
technique to identify RA-related bone involvement in hands
compared with DXA-BMD measurement, but further studies are
needed to explore this hypothesis.
Introduction
Periarticular bone loss and erosions on radiographs are char-
acteristic features of bone damage in rheumatoid arthritis (RA)
[1], and both features are caused by joint inflammation [2].
Substantial data suggest a common cellular pathway for both
periarticular bone loss and erosions involving the osteoclast
cell [3,4]. In active RA there is an excess production of proin-
flammatory cytokines (for example, IL-1 and TNFα), which
stimulates receptor activator of nuclear factor kB ligand
(RANKL) to activate the osteoclast cell [3-5].
Because periarticular bone loss is an early finding and may
also precede erosions on radiographs [6], quantitative hand
bone measurements that capture periarticular osteoporosis
have been proposed as outcome measures in early RA [7,8].
Inflammation of the joints, however, is not restricted to the
early phase of the RA disease, but may be present during the
entire disease course [9]. Hand bone loss could therefore
potentially be an outcome measure in RA patients with pro-
longed disease.
AOT = antiresorptive osteoporotic treatment; BMD = bone mineral density; DAS 28 = disease activity score including 28 joints; DMARD = disease-
modifying antirheumatic drugs; DXA = dual-energy X-ray absorptiometry; DXR = digital X-ray radiogrammetry; IL = interleukin; MCI = metacarpal cor-
tical index; MHAQ = Modified Health Assessment Questionnaire; RA = rheumatoid arthritis; TNF = tumor necrosis factor.Arthritis Research & Therapy    Vol 9 No 4    Hoff et al.
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Several devices for quantitative bone measurements have
been developed [10] – for example, quantitative computer
tomography, measuring cortical and trabecular bone sepa-
rately; quantitative ultrasound, providing measures that may
reflect bone quality; dual-energy X-ray absorptiometry (DXA),
which measures total cortical and trabecular bone; and digital
X-ray radiogrammetry (DXR), which measures cortical bone
only. DXA is considered the gold standard among bone meas-
urement devices for assessment of bone density at the hip and
the spine. DXA has not, however, been shown to be superior
to other bone measure devices, such as DXR, in the hand [11].
DXR, which is a further development and digitalized version of
the conventional radiogrammetry [12], is a new promising
method for assessment of cortical hand bone loss [13].
The understanding of hand bone loss as an outcome measure
in RA is mainly limited both due to lack of data from longitudi-
nal studies and due to the small number of patients included
in previous studies. Only a few studies have examined associ-
ations between disease factors and hand bone loss in RA, and
most of them have focused on patients with early disease [6-
8,11,14,15]. Data from two longitudinal studies by Deodhar
and colleagues suggest that whole hand DXA bone mineral
density (BMD) loss only takes place in the first 2–3 years of
the RA disease process, which may limit the use of hand DXA-
BMD as an outcome measure in prolonged disease [7,15].
Only a few studies have compared hand DXA-BMD with hand
cortical bone DXR-BMD in RA [11,16].
The aim of the present study was to explore hand bone loss as
a disease outcome measure in established RA assessed by
DXR and by DXA and to compare the two methods.
Materials and methods
Patients
The 215 RA patients (45 males and 170 females) included in
the present study were recruited from a longitudinal cohort of
366 RA patients (aged 20–70 years) [17], all patients fulfilling
the American College of Rheumatology (ACR) criteria and
enrolled in the Oslo RA register [18]. Two-year changes in
generalized bone loss at the hip and the spine from this origi-
nal cohort have previously been described in detail [17]. In the
present study, only patients with hand radiographs and DXA-
BMD measurement of the hand at baseline and 2-year follow-
up were included; 151 patients missed at least one BMD
measurement and were excluded. There were no other exclu-
sion criteria.
Demographic and clinical variables
The demographic and clinical characteristics of the patients
(Table 1) were recorded by a combination of self-reported
questionnaires, interview and clinical investigation, as previ-
ously reported [17]. In short, the clinical examination included
28-swollen and tender joint counts as well as routine labora-
tory tests. The disease activity score including 28 joints
(DAS28) was computed based on the erythrocyte sedimenta-
tion rate [19]. Patients with a titer ≥64 of the Waaler–Rose
reaction were classified as rheumatoid factor-positive. The
physician's global assessment of disease activity was meas-
ured on a visual analogue scale (0–100 mm). Use of antire-
sorptive osteoporotic treatment (AOT) with bisphosphonates
or hormone replacement therapy, prednisolone and disease-
modifying antirheumatic drugs (DMARD) was recorded. Phys-
ical disability was measured by the Modified Health Assess-
ment Questionnaire (MHAQ) (eight items; range of scores 1–
4) [20].
Bone mineral density measurements
The DXR-BMD and the DXR metacarpal cortical index (MCI)
was measured by the Pronosco X-posure system™ (version
2.0; SECTRA, Linköping, Sweden) [13], a computer version of
the traditional technique of radiogrammetry [12]. The compu-
ter automatically recognizes, on standard radiographs, regions
of interest around the narrowest part of the second, third and
fourth metacarpal bones of the hand. In each region, the corti-
cal thickness, bone width and porosity is measured 118 times
per centimeter. The final BMD estimate is defined as: DXR-
BMD = c × VPAcomb × (1 – p), where c is a constant (deter-
mined such that DXR-BMD on average is equal to the mid-dis-
tal forearm region of the Hologic QDR-2000 device (Hologic
Inc., Bedford, MA, USA)), VPA is the volume per area and p is
the porosity. The DXR method has previously been described
in detail [13,21]. The MCI is defined as the combined cortical
thickness divided by the outer cortical diameter and is a rela-
tive measure independent of bone size or bone length [22,23].
The DXR method has improved the precision of MCI for diag-
nosing cortical bone loss [12,23]. All radiographs of the hand
were acquired by a Siemens Multix Polymat equipment (Sie-
mens AG, Erlangen, Germany) (AGFA Curix film; film focus
distance, 1 m; X-ray tube voltage, 55 kV; exposure dose, 6
mAs).
Standardized BMD measurements for the left and right hands
and the total hip and spine (L2–L4) were performed using the
same DXA equipment (Lunar Expert; Lunar Corporation, Mad-
ison, WI, USA) both at baseline and follow-up. All procedures
were in accordance with the manufacturer's standardized pro-
cedures for hand BMD measurements.
For the DXR-BMD most previous studies have used the non-
dominant hand [11,14], while for DXA measures there is no
consistency and both hands [8], the right hand [15,24] and
the nondominant hand [11] have all been used. To avoid bias
regarding dominant and nondominant hands and to achieve
better precision, we used the mean of both hands. Only
patients who had complete measurements for both DXA-BMD
and DXR-BMD in both hands were therefore included.Available online http://arthritis-research.com/content/9/4/R81
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Precision of bone mineral density measurements
Short-time precision was calculated from the material of 28
healthy individuals who underwent duplicate hand BMD meas-
urements and duplicate hand radiographs of both hands with
repositioning of the hand between each assessment. Short-
time precision based on the duplicate measurements,
expressed as the percentage coefficient of variation, was
0.28% for the DXR-BMD hand and was 0.76% for the DXA-
BMD hand. Long-time precision for DXR-BMD based on daily
measurement of one hand radiograph was 0.25%, and long-
time precision for the DXA-BMD hand based on daily meas-
urements of the aluminum spine phantom supported by the
Lunar Expert (Lunar Corporation) was 0.80%
Ethics and legal aspects
The study was approved by the regional committee for ethics
and medical research.
The Norwegian Data Inspectorate approved the registry of RA
patients in Oslo.
Statistical analysis
The statistical analyses were carried out using the SPSS pro-
gram, version 13 (SPSS Inc., Chicago, IL, USA).
Nonparametric tests were used for comparisons between
groups (Mann–Whitney and Kruskal–Wallis tests) and within
groups (Wilcoxon test) because of a skewed distribution of
data. Results are presented as the median and interquartile
range (25th–75th percentiles). Bivariate correlations were
tested using Spearman's correlation.
Bone loss over time was expressed as a negative value.
Changes of BMD measurements were compared across
groups according to the disease duration (cut-off 3 years),
baseline DAS28 (<3.2, low disease activity; 3.2–5.1, moder-
ate disease activity; >5.1, high disease activity) and baseline
MHAQ score (<1.50, 1.50–1 99, ≥2). The 3-year cut-off value
for disease duration was chosen for pragmatic reasons due to
a low number of included patients with short disease duration
and reports in the literature suggesting hand bone loss only
takes place in the first 3 years of disease duration [7].
Table 1
Patient characteristics at baseline and at 2-year follow-up
Variable n Baseline At 2-year follow-up
Demographic
Age (years) 215 57.4 (49.1–64.7)
Female 215 170 (79.0%)
Menopause 170 111 (65.3%)
Body mass index (kg/m2) 215 23.9 (21.3–26.2) 24.0 (21.5–26.2)
Smoker 210 65 (31.0%) 67 (31.9%)
Disease
Disease duration (years) 215 9 (4–16)
Age at disease onset (years) 215 45.0 (33.0–53.0)
Rheumatoid factor-positive 202 97 (48.0%)
Physician's global assessment score (visual analogue scale, 0–100 mm) 203 19.0 (8.0–39.8) 17.6 (8.5–30.0)
Modified Health Assessment Questionnaire (range 1–4) 214 1.50 (1.13–1.75) 1.50 (1.13–1.87)
Erythrocyte sedimentation rate (mm/hour) 210 16 (9–27) 14 (8–27)
Disease activity score including 28 joints 202 4.04 (3.17–4.96) 4.26 (3.36–5.06)
Medication
Ever user of disease-modifying antirheumatic drugs 213 177 (83.1%) 177 (83.1%)
Corticosteroids 208 79 (37.9%) 85 (40.9%)
User of corticosteroids in the 2-year period 208 93 (44.7%)
Antiresorptive osteoporosis treatment 209 47 (22.5%) 68 (32.5%)
Ever user of antiresorptive osteoporosis treatment 209 92 (44.0%)
Calcium and/or vitamin D 210 113 (53.8%) 155 (73.8%)
Data presented as the median (interquartile range) or as the absolute value (%).Arthritis Research & Therapy    Vol 9 No 4    Hoff et al.
Page 4 of 8
(page number not for citation purposes)
The predictive values of disease duration, DAS28 and MHAQ
score were also tested in a multiple linear regression model,
with the change of hand BMD as the dependent variable and
with adjustments for age, gender, rheumatoid factor and use
of medication (AOT, prednisolone and DMARD). Enter and
stepwise procedures were used. According to inspection of
Q–Q plots, the distribution of residuals showed acceptable fit
to the normal distribution regarding hand DXR-BMD, whereas
one outlier was identified in the analysis with hand DXA-BMD
as the dependent variable. This analysis was therefore per-
formed both with and without the outlier.
Two tailed P values of 0.05 or less were considered statisti-
cally significant.
Results
Patient characteristics at baseline and at follow-up are pre-
sented in Table 1. The 215 examined patients in this study had
shorter disease duration (9 years versus 15 years, P < 0.01),
lower disease activity measured by the DAS28 (4.00 versus
4.62, P < 0.01), lower global assessment (19 versus 30, P <
0.01) and used less prednisolone (37% versus 54%, P <
0.01) compared with those who were not included (n = 151)
from the original cohort (n = 366). The two groups were similar
regarding age, gender, body mass index, smoking habits, rheu-
matoid factor, age of disease onset, erythrocyte sedimentation
rate, menopause in women and use of DMARD and AOT.
Change in bone mineral density
In the entire group, a significant loss in hand BMD was seen at
2 years as measured by DXR-BMD (-0.90%) and DXR-MCI (-
1.18%), but not as measured in the DXA-BMD hand (0.00%)
(Figure 1). A significant bone loss was also observed for the
DXA-BMD in the total hip (-0.72%) and in the spine L2–L4 (-
0.78%) (Figure 1).
The correlation (r value) between the DXR-BMD hand and the
DXA-BMD hand was 0.88 (P < 0.001) for baseline values and
was 0.35 (P < 0.001) for 2-year BMD changes. Correlations
between the change in the DXA hand and in the DXA total hip
and spine were 0.35 (P  < 0.001) and 0.18 (P  = 0.01),
whereas correlations between the change in the DXR hand
and DXA total hip and spine were 0.23 (P = 0.001) and 0.10
(P = 0.16), respectively. The DXR-MCI was highly correlated
with the DXR-BMD both at baseline (r = 0.86, P < 0.001) and
as the percentage change over 2 years (r = 0.94, P < 0.001).
Association between disease duration and bone loss
At baseline 37 patients had a disease duration of 3 years or
less and 178 patients had a disease duration longer than 3
years. DXA-BMD hand bone loss was only observed in
patients with disease duration less than 3 years and not in
patients with longer disease duration (-0.96% versus 0.24%,
P  < 0.01) (Table 2), whereas loss of DXR-BMD (-0.46%
versus -0.93%, P = 0.76) as well as loss of DXR-MCI (-0.89
versus -1.29, P = 0.66), of the DXA-BMD total hip (-0.26%
versus -0.76%, P = 0.51) and of the DXA-BMD spine (-0.71%
versus -0.82%, P = 0.64) occurred independent of disease
duration. The changes in BMD in the subgroups (according to
disease duration) were all significant except for the DXA-BMD
hand patients with disease duration longer than 3 years (P =
0.26) and the DXA-BMD spine (P = 0.60) and DXA-BMD total
hip patients with disease duration less than 3 years (borderline
significant, P = 0.06).
The patients with short and long disease duration were com-
parable with regard to demographic variables, disease activity
and treatment with DMARD and corticosteroids, but AOT was
used less frequently by patients with short disease duration
than by patients with long disease duration (16.1% versus
35.5%, P = 0.04). The difference in DXA hand bone loss
across patients with short and long disease duration, however,
was also significant in the subgroup not using AOT (-1.41%
Figure 1
Bone loss in 215 rheumatoid arthritis patients followed for 2 years Bone loss in 215 rheumatoid arthritis patients followed for 2 years. 
Bone loss assessed by digital X-ray radiogrammetry (DXR) bone min-
eral density (BMD) and metacarpal cortical index (MCI) of the hand, 
and by dual-energy X-ray absorptiometry (DXA) BMD of the hand, total 
hip and spine (L2–L4).Available online http://arthritis-research.com/content/9/4/R81
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versus 0.11%, P = 0.02). These findings are consistent in a
linear regression model adjusted for other variables that may
influence hand bone loss (Table 3). The analysis was per-
formed both with and without the outlier, with the same results.
Association between disease activity score and hand 
bone loss
At baseline 55 patients had low disease activity, 103 patients
had moderate disease activity and 44 patients had high dis-
ease activity. Bone loss changes, as measured by DXR-BMD,
differed across patients with different levels of disease activity
(low, -0.29%; moderate, -1.13%; and high, -1.03%; P = 0.03),
and were borderline significant for DXR-MCI (-0.76, -1.34 and
-1.13, P = 0.06) (Table 2). No significant difference in DXA-
measured hand BMD change was found for the low, moderate
and high levels of disease activity (-0.40% versus 0.26% ver-
sus 0.04%, respectively; P = 0.40). Hand BMD baseline val-
ues, however, were significantly lower in the group with high
disease activity in both the DXR-BMD and the DXA-BMD
(Table 2).
Table 2
Comparison of the baseline and the change in hand bone mineral density
Disease duration DAS28 at baseline MHAQ at baseline
≤3 years >3 years P value* <3.2 3.2–5.1 >5.1 P value <1.50 1.50–1.99 ≥2.0 P value
n 37 178 <0.01 55 103 44 <0.01 102 78 34 <0.01
Age (years) 55.4
(43–62)
58.0
(50–65)
0.10 53.5
(39–61)
55.8
(49–64)
62.2
(57–67)
<0.01 53.6
(41–64)
58.9
(52–64)
61.2
(54–67)
<0.01
DXA-BMD 
(g/cm2)
0.39
(0.34–0.43)
0.36
(0.31–0.41)
0.04 0.40
(0.36–0.43)
0.38
(0.32–0.42)
0.33
(0.28–0.38)
<0.01 0.38
(0.33–0.43)
0.37
(0.31–0.41)
0.34
(0.30–0.39)
0.13
DXA-BMD 
change (%)
-0.96
(-4.4 to 1.5)
0.24
(-1.4 to 2.1)
<0.01 -0.40
(-2.4 to 1.8)
0.26
(-1.3 to 2.2)
0.04
(-3.4 to 2.2)
0.40 0.11
(-2.5 to 2.1)
0.0
(-1.2 to 2.0)
-0.12
(-4.1 to 2.2)
0.75
DXR-BMD 
(g/cm2)
0.57
(0.50–0.61)
0.51
(0.44–0.56)
<0.01 0.56 
(0.50–0.61)
0.53
(0.45–0.58)
0.46
(0.38–0.52)
<0.01 0.54
(0.49–0.59)
0.49 
(0.44–0.57)
0.50
(0.40–0.53)
<0.01
DXR-BMD 
change (%)
-0.46
(-3.6 to 0.2)
-0.93
(-2.8 to 0.3)
0.76 -0.29
(-1.6 to 0.7)
-1.13
(-3.2 to 0.1)
-1.03
(-4.3 to 0.5)
0.03 -0.80
(-2.6 to 0.1)
-0.94
(-2.8 to 0.5)
-0.81
(-3.7 to 0.5)
0.90
DXR-MCI 0.40
(0.37–0.49)
0.37
(0.31–0.45)
<0.01 0.41
(0.34–0.48)
0.39
(0.33–0.46)
0.32
(0.27–0.38)
<0.01 0.40
(0.33–0.48)
0.37
(0.31–0.43)
0.33
(0.29–0.41)
<0.01
DXR-MCI 
change (%)
-0.89
(-5.5 to 0.0)
-1.29
(-3.1 to -0.1)
0.66 -0.76
(-1.8 to 0.3)
-1.34
(-3.4 to -0.4)
-1.13
(-5.2 to -0.2)
0.06 -1.33
(-3.1 to -0.3)
-1.20
(-3.2 to 0.3)
-0.71
(-5.0 to 0.0)
0.74
Digital X-ray radiogrammetry (DXR) bone mineral density (BMD), DXR metacarpal cortical index (MCI) and dual-energy X-ray absorptiometry (DXA) BMD assessed for 
levels of disease duration, for disease activity (disease activity score including 28 joints (DAS28)) and for physical function (Modified Health Assessment Questionnaire 
(MHAQ)) in rheumatoid arthritis patients. Data presented as the medians (interquartile range). *P values between subgroups.
Table 3
Risk factors for hand bone loss in a multivariate linear regression model
DXA-BMD hand percentage change DXR-BMD hand percentage change DXR-MCI percentage change
B (standard error) P value B (standard error) P value B (standard error) P value
Disease activity score including 28 
joints
0.09 (0.25) 0.73 -0.47 (0.16) 0.003 -0.47 (0.18) 0.009
Disease duration <3 years -2.84 (0.88) 0.001 0.46 (0.55) 0.40 0.45 (0.63) 0.47
Baseline BMD (g/cm2)/MCI -9.70 (5.01) 0.05 -3.80 (2.51) 0.13 -5.79 (2.81) 0.04
Prednisolone during 2-year follow-
up (no/yes)
0.44 (0.69) 0.53 -0.03 (0.43) 0.95 -0.41 (0.49) 0.40
Ever disease-modifying 
antirheumatic drug user (no/yes)
-0.31 (0.90) 0.73 -0.58 (0.55) 0.30 -0.56 (0.63) 0.38
Ever antiresorptive osteoporosis 
treatment user (no/yes)
0.78 (0.70) 0.27 0.03 (0.42) 0.95 -0.05 (0.47) 0.91
R2 0.11 0.05 0.06
B values are unstandardized coefficients. Age, gender, rheumatoid factor and the Modified Health Questionnaire were also tested, but did not 
influence the results. DXA, dual-energy X-ray absorptiometry; DXR, digital X-ray radiogrammetry; BMD, bone mineral density; MCI, metacarpal 
cortical index.Arthritis Research & Therapy    Vol 9 No 4    Hoff et al.
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The correlation (r value) between the DAS28 at baseline (con-
tinuous scale) and the hand DXR-BMD change was -0.19 (P
= 0.01), between the DAS28 and the DXR-MCI change was -
0.16 (P = 0.03), and between the DAS28 and the hand DXA-
BMD change was 0.08 (P = 0.27). Patients in the group with
high disease activity were significant older than the group with
lowest disease activity. In a multivariate model, however, dis-
ease activity was independently associated with the percent-
age change in DXR-BMD (B = -0.47, P < 0.01) (Table 3) and
with the DXR-MCI (B = -0.47, P < 0.01), after adjusting for
other variables that could influence hand bone change as well
as age.
Association between functional disability (MHAQ score) 
and hand bone loss
At baseline, 102 patients had a MHAQ score less than 1.50,
78 patients a score between 1.50 and 1.99, and 34 patients
had a MHAQ score of two or more. The patient with highest
MHAQ score was older than patients with lower MHAQ
scores. Regarding correlation between the MHAQ score at
baseline and the change in hand DXR-BMD, the DXR-MCI
hand and the DXA-BMD hand were nonsignificant both for
continuous values (r = 0.00, P = 0.96; r = 0.03, P = 0.70; and
r = -0.05, P = 0.51) and for groups (r = 0.02, P = 0.82; r =
0.05, P = 0.47; and r = -0.02, P = 0.82) for the MHAQ score
ranges <1.5, 1.50–1.99 and ≥2, respectively. There were no
differences in the change in hand BMD dependent on the
MHAQ group either in the DXR-BMD hand, the DXR-MCI
hand or the DXA-BMD hand. Baseline values, however, were
significantly higher in the group with the lowest MHAQ score
with regards to DXR-BMD and DXR-MCI (Table 2). No such
findings were seen regarding DXA measurements.
Associations between treatment and hand bone loss
At follow-up 33% of the patients were current users of AOT
(88% used hormone replacement therapy and 12% used
bisphosphonates) and 44% were ever users. A significant dif-
ference in DXA-BMD hand change was found between users
and nonusers of AOT (0.44% versus 0%, P = 0.04). No such
difference was seen for DXR-BMD (-1.01% versus -0.66%, P
= 0.54) or DXR-MCI (-1.14 versus -1.19, P = 0.60) in users
versus nonusers of AOT. Use of AOT, however, was not sig-
nificantly associated with the change in DXA-BMD in the mul-
tivariate analyses (Table 3).
No significant difference in hand bone change was seen
between ever users (83%) and never users (17%) of DMARD
regarding the DXR-BMD hand (-0.90% versus -0.85%, P =
0.29), the DXR-MCI hand (-1.19 versus -0.78, P = 0.17) or the
DXA-BMD hand (0.27% versus -0.34%, P = 0.22). During the
2-year follow-up 45% of patients had used prednisolone and
41% were current users at follow-up with a mean dose of 5.7
mg. No significant difference in change of hand BMD was
observed between users and nonusers of prednisolone
regarding DXR-BMD (-0.94% versus -0.66%, P = 0.19) or
DXA-BMD (0.62% versus 0%, P  = 0.17), but a group
difference between users and nonusers was observed for
DXR-MCI (-1.42 versus -0.98, P = 0.05). Prednisolone users,
however, had a significantly higher disease activity than non-
users (data not shown) and the significant association
between prednisolone and the change in DXR-MCI disap-
peared in the multivariate analysis (Table 3).
Discussion
The present study had two main findings. First, total hand bone
loss measured by DXA-BMD seems to occur only in the first
years of RA disease, whereas DXR-BMD-measured cortical
hand bone loss occurs both in early stages as well as late
stages of the disease. Second, patients with high disease
activity at baseline lost more DXR-BMD and DXR-MCI than
patients with low disease activity. In the present study there
were only marginally differences between DXR-BMD and
DXR-MCI, and our main focus in the discussion will therefore
be on DXR-BMD.
A discrepancy in loss of DXA-BMD hand between early dis-
ease and long-standing disease has previously been sug-
gested based on the results of two longitudinal studies [7,15].
Hand bone loss was only observed in the first 3 years and then
stabilized over the next 2 years in a longitudinal study of 29
patients with RA [7]. Degenerative bone changes and
increased inflammation in the small joints of the hand in the
first years of the disease has been suggested partly to explain
this finding [25]. As DXA-BMD measures both trabecular and
cortical bone, a third explanation could be that the rate of
trabecular and cortical bone loss is different in early stages
versus late stages of the disease. Even if DXR-BMD hand
bone loss occurs during the whole RA disease course, the
bone loss has been shown to be more rapid in early disease
compared with more prolonged disease [14]. Böttcher and
colleagues reported annual DXR-BMD loss in the first 6 years
of the disease to be as high as 11%, with a subsequent
decline to 3–4% over the next years [14].
Interestingly, changes in the DXA-BMD in the total hip and
spine were independent of the disease duration. There are few
studies that have compared periarticular and generalized oste-
oporosis among RA patients [8,26-28]. Hand bone loss in
early RA has been shown to occur more rapidly than bone loss
in the hip and the spine [8,28]. Radiographic joint damage has
been shown to be more strongly correlated with low hand
DXR-BMD than DXA-BMD at the hip and the spine [26,27]. In
a randomized, placebo-controlled trial among early RA
patients, use of prednisolone reduced hand bone loss [29].
These data suggest that the effect of inflammation on hand
bone in RA may be greater than the effect on other bones (for
example, spine and hip). The generalized bone loss may be
more associated with the prolonged course of RA, including
the use of corticosteroids and immobility [30].Available online http://arthritis-research.com/content/9/4/R81
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The other main finding in the present study is that patients with
high disease activity at baseline lost more DXR-BMD than
patients with low disease activity. Surprisingly, this association
was not found between DXA-BMD hand bone loss and base-
line disease activity, and this lack of association was consist-
ent in both patients with short and long disease durations
(data not shown). Some previous studies in early RA, however,
have shown that disease activity is associated with both DXA-
BMD-measured generalized bone loss [31] as well as local-
ized bone loss [8]. Gough and colleagues [31] found that early
RA patients with active disease (defined as mean C-reactive
protein >20 mg/l over 12 months) showed greater generalized
bone loss at the hip and the spine compared with patients with
lower disease activity. Haugeberg and coworkers [8] found
that C-reactive protein independently predicted hand BMD
loss in patients with early undifferentiated arthritis who, during
a 12-month follow-up, developed RA. Explanations for contra-
dictory findings between these two studies and our study may
be differences in disease activity and disease duration in the
examined study cohorts.
The association between disease activity and DXR-BMD hand
bone loss in our study was shown when dichotomizing the
patients into groups based on disease activity (Table 2) and in
linear multivariate analyses (Table 3). These consistent associ-
ations combined with the demonstration of bone loss inde-
pendent of disease duration (Table 3) suggest that DXR-BMD
is a robust outcome measure in RA, reflecting the inflammatory
disease process in early stages as well as late stages of the
disease. Only a few previous studies have been carried out
with DXR-BMD loss as the key outcome measure [11,32].
Jensen and colleagues [11] found in patients with early RA
(<2 years) that DXR-BMD was more strongly associated with
disease activity than hand DXA-BMD. In a cross-sectional
study, Böttcher and colleagues found that DXR-BMD was
negatively correlated with disease activity measured by the
DAS28 [32].
In the present study the hand bone loss measured by both
DXR-BMD and DXA-BMD was less than that reported by
other workers. Jensen and colleagues [11] found a loss of
DXR-BMD of 5% over 2 years in an early RA disease group,
and Haugeberg and colleagues found that the DXA-BMD
hand loss was reduced by 4.3% in early RA disease patients
[8]. One explanation for the lower rate of hand bone loss in the
present study may be that our cohort was obtained from an
observational study of patients with different levels of disease
activity and duration. The recruitment of these patients from a
validated RA register is also a strength of the present study as
the results provide insight into what takes place in the real
world of RA patients regarding hand bone loss [18]. Another
reason for the less bone loss may be that the DXA-BMD hand
was assessed as a whole hand and not around selected finger
joints, which according to the cross-sectional study by Alen-
feld and colleagues [33] has been suggested to be the best
site to capture periarticular bone loss in RA. There are disad-
vantages using periarticular regions compared with the whole
hand, however, which include poorer precision and poorer fea-
sibility [33]. Because of skewed data, median values were
used instead of mean values, neutralizing the effect of
extremes on the BMD results.
The limitations of the present study were that relatively few
patients had short disease duration. The effect of medication
on the bone was also difficult to evaluate because patients had
no standardized treatment but were treated according to clin-
ical judgment. Adjusting for medication use in the multivariate
analyses had no significant effect on BMD change either on
the DXR-BMD hand or the DXA-BMD hand. A study with a ran-
domized controlled design would give stronger evidence for
the effects of medication.
Onepotential limitation using quantitative bone measures as
an outcome measure in RA is the influence of normal bone
loss, which also takes place in healthy adult subjects. Normal
bone loss for DXR-BMD has only been examined in cross-sec-
tional studies reporting an annual rate of bone loss between
0.4% and 0.9% [22,34-36]. For DXA-BMD hip and spine
bone loss, using cross-sectional data has been shown to over-
estimate the rate ofnormal bone loss compared with longitudi-
nal studies [37]. In the multivariate model, however, age was
not a significant predictor for hand bone loss over 2 years
either for DXR-BMD or for DXA-BMD (data not shown).
Conclusion
We suggest that hand DXA-BMD can only be used as an out-
come measure in RA in the first years of the disease, whereas
DXR-BMD may be used as a marker for disease activity and
bone loss during the whole disease process, both in early dis-
ease as well as prolonged disease. The reason for this dis-
crepancy is not clear and additional studies are warranted to
further explore this hypothesis.
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